Stock Research: Edwards Lifesciences

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Edwards Lifesciences

NYQ:EW US28176E1082
78
  • Value
    10
  • Growth
    81
  • Safety
    Safety
    94
  • Combined
    70
  • Sentiment
    61
  • 360° View
    360° View
    78
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Edwards Lifesciences Corporation is a global company focused on structural heart disease. The company operates in the medical devices industry with products including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It operates in the United States, Europe, Japan, and the Rest of World. In the last fiscal year, the company had 15800 employees, a market cap of $45057 million, profits of $4322 million, and revenue of $5440 million.

more

ANALYSIS: With an Obermatt 360° View of 83 (better than 83% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Edwards Lifesciences are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Edwards Lifesciences. The consolidated Growth Rank has a good rank of 81, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 81% of competitors in the same industry. The consolidated Safety Rank at 94 means that the company has a financing structure that is safer than 94% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 63, which means that professional investors are more optimistic about the stock than for 63% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 10, meaning that the share price of Edwards Lifesciences is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 90% of alternative stocks in the same industry. ...read more

more
Index
D.J. US Health Care
D.J. US Medical Equipment
S&P 500
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 26-May-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
10 13 10 5
Growth
81 23 51 91
Safety
Safety
94 100 93 77
Sentiment
61 58 39 54
360° View
360° View
78 25 51 72
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
41 24 14 30
Opinions Change
50 67 38 53
Pro Holdings
n/a 86 72 38
Market Pulse
67 46 59 85
Sentiment
61 58 39 54
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
10 13 10 5
Growth
81 23 51 91
Safety Safety
94 100 93 77
Combined
70 29 64 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
22 13 18 9
Price vs. Earnings (P/E)
16 29 34 27
Price vs. Book (P/B)
35 43 16 19
Dividend Yield
1 1 1 1
Value
10 13 10 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
54 60 43 47
Profit Growth
87 21 36 53
Capital Growth
50 25 86 86
Stock Returns
63 49 55 97
Growth
81 23 51 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
87 83 76 67
Refinancing
28 44 17 7
Liquidity
100 100 100 96
Safety Safety
94 100 93 77

Similar Stocks

Discover high‑ranked alternatives to Edwards Lifesciences and broaden your portfolio horizons.

Toll Brothers

NYQ:TOL
Country: USA
Industry: Homebuilding
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Keurig Dr Pepper

NSQ:KDP
Country: USA
Industry: Soft Drinks
Size: X-Large
Full Stock Analysis

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: